Long-Term MINT Data Support Durable Response to Inebilizumab in… | HappeningNow.news
Published Date: October 20, 2026

Health · 3 views

Long-Term MINT Data Support Durable Response to Inebilizumab in Myasthenia Gravis

(MedPage Today) -- One-year results from the open-label extension of the phase III MINT trial presented at the American Association of Neuromuscular and Electrodiagnostic Medicine annual meeting showed that the benefits of inebilizumab…

Source Summary Published 2h 13m ago Brief Under 1 min brief
Story intelligence
Coverage Single outlet Single-outlet story
Views 3 Community interest
Brief read Under 1 min brief 34 words

Summary

(MedPage Today) -- One-year results from the open-label extension of the phase III MINT trial presented at the American Association of Neuromuscular and Electrodiagnostic Medicine annual meeting showed that the benefits of inebilizumab (Uplizna

Read original at MedPage Today

Coverage Context

Part of MINT coverage 3 tracked stories
Explore MINT View timeline
Category Health
Source MedPage Today
Return to Frontpage

Support HappeningNow

Independent AI-powered news analysis is reader-supported. Your contribution helps cover infrastructure, summaries, and continued platform development.

Support HappeningNow

Report an issue with this page